MartinTallmanMD

PubMed

• 36 citations
  Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
  Hagop M. Kantarjian, S. Padmanabhan, Wendy Stock, Martin S. Tallman, Gregory A. Curt
  Investigational New Drugs. 2012-06-01
• 2251 citations
  Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therape...
  Bruce D. Cheson, John M. Bennett, Kenneth J. Kopecky, Thomas Büchner, Cheryl L. Willman
  Journal of Clinical Oncology. 2003-12-15
• 166 citations
  NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
  Susan O'Brien, Ellin Berman, Borghaei H, Daniel J. DeAngelo, Marcel P. Devetten
  Journal of the National Comprehensive Cancer Network. 2009-10-01

Journal Articles

• Extramedullary Acute Myeloid Leukemia Presenting in Young Adults Demonstrates Sensitivity to High Dose Anthracycline: Subset Analysis from ECOG-ACRIN 1900  
  Selina M Luger, Ross L Levine, Martin S Tallman, Haematologica
• Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
  Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML  
  Alexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood
• Join now to see all

Abstracts/Posters

• Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Acute Leukemia with Lineage Infidelity: Mixed Phenotype AML Exhibits a Distinct Immunophenotype with Clinical Features Overlapping Mixed Phenotype Acute Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelody...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
  Martin S. Tallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hypofibrinogenemia and Disseminated Intravascular Coagulation Rarely Complicate Treatment-Naive Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Changing Game Plan for Acute Lymphocytic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all

Other

• Clinical features and diagnosis of hairy cell leukemia 
  Tallman MS, Aster JC
  http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-hairy-cell-leukemia
  UpToDate, Wolters Kluwer Health - 2013-04-02
• Treatment of hairy cell leukemia 
  Tallman MS
  http://www.uptodate.com/contents/treatment-of-hairy-cell-leukemia
  UpToDate, Wolters Kluwer Health - 2012-12-12